Table 1.
Condition | Gene | Count | Rate (%) |
---|---|---|---|
Deafness, Autosomal Recessive 1A; DFNB1A | GJB2 | 378 | 24.50 |
Thalassaemia, Alpha- | HBA1/HBA2 | 38 | 8.90a |
Spinal Muscular Atrophy, Type I | SMN1 | 9 | 2.11a |
Carnitine Deficiency, Systemic primaryb | SLC22A5 | 32 | 2.07 |
Citrullinemia Type II, Neonatal-onsetb | SLC25A13 | 28 | 1.81 |
Wilson’s Disease | ATP7B | 27 | 1.75 |
Pendred Syndrome | SLC26A4 | 27 | 1.75 |
Krabbe Diseaseb | GALC | 24 | 1.56 |
POLG-Related Disorders | POLG | 20 | 1.30 |
Usher Syndrome, Type 2A | USH2A | 18 | 1.17 |
Hb Beta Chain-Related Haemoglobinopathy (including Beta Thalassaemia and Sickle Cell Disease) | HBB | 17 | 1.10 |
Glycogen Storage Disease, Type Ia | G6PC | 14 | 0.91 |
Glycogen Storage Disease II | GAA | 13 | 0.84 |
Phenylketonuria | PAH | 12 | 0.78 |
Methylmalonic Aciduria due to Methylmalonyl-CoA Mutase Deficiency | MMUT | 12 | 0.78 |
Cystic Fibrosis | CFTR | 12 | 0.78 |
aCarrier rate was calculated from genome sequencing samples (n = 427) but not exome sequencing samples.
bRecessive Conditions not screened according to ACMG 2021 practice protocol.